Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M

Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

December 13, 2022

Medical Devices

Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.

Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences

January 18, 2024

Medical Devices

Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.

Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer

December 30, 2021

Medical Devices

Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.

Altaris Capital Partners Acquires Perrigo's Prescription Pharmaceuticals Business (Padagis)

March 1, 2021

Pharmaceuticals

Altaris Capital Partners has acquired Perrigo's prescription pharmaceuticals business for $1.55 billion and completed the carve-out, renaming the business Padagis. The business, a leader in generic prescription pharmaceuticals with more than 1,300 employees across six U.S. and Israeli locations and a portfolio of 200+ product families (800 SKUs), will be headquartered in the United States as a standalone company.

3M Acquires Acelity (and KCI) from Apax-led Consortium for $6.725B

October 11, 2019

Medical Devices

3M has completed the acquisition of Acelity and its KCI subsidiaries from funds advised by Apax Partners and consortium partners Canada Pension Plan Investment Board and the Public Sector Pension Investment Board for $6.725 billion. The transaction transfers Acelity — a global leader in advanced wound care and negative pressure wound therapy headquartered in San Antonio — to 3M, expanding 3M’s medical products capabilities.

Altaris Acquires Minaris Regenerative Medicine from Resonac

September 23, 2024

Healthcare Services

Altaris, LLC has acquired Minaris Regenerative Medicine from Resonac Corporation, making Minaris a wholly owned portfolio company of Altaris. Minaris is a cell therapy CDMO with six facilities across the United States, Germany and Japan and more than 500 employees; the deal advances Altaris' strategic initiative to build capabilities in cell and gene therapy manufacturing.